Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

703.O1.8 Immunotherapy

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
Golden Gate Hall (San Francisco Marriott)
Moderators:
Hermann Einsele, MD and A. John Barrett, MD, FRCP
7:00 AM
GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid MalignanciesClinically Relevant Abstract

Vincent Ho, MD1, Glenn Dranoff, MD2*, Haesook Kim, PhD3*, Matthew Vanneman2*, Mildred Pasek2*, Corey Cutler, MD2*, John Koreth, MBBS2*, Edwin Alyea, MD4, Joseph H Antin, MD2*, Ritz Jerome, MD2* and Robert J Soiffer, MD2*

1Hematologic Oncology, Dana-Farber Cancer Inst., Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Computational Biology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Inst., Boston, MA

7:15 AM
Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple MyelomaClinically Relevant Abstract

David Avigan, MD1, Jacalyn Rosenblatt, MD1, Baldev Vasir, PhD2*, Zekui Wu, MD2*, Adam Bissonnette2*, Poorvi Somaiya1*, Claire MacNamara1*, Lynne Uhl, MD1*, Irit Avivi, MD3*, Tami Katz, Ph.D3*, Corrine Zarwan, MD1*, Robin Joyce, MD1*, James D. Levine, MD1*, Vassiliki Boussiotis, MD1*, Dimitrios Tzachanis, MD1*, Karen Lowe, RN1*, Dilani Dombagoda1*, Nancy Giallombardo, NP1*, Jamie Mortellite, NP1*, Katharine Conway, NP1*, Donna Fitzgerald, PA1*, Paul Richardson, MD2*, Kenneth Anderson, MD2*, Nikhil C. Munshi, MD2*, Michal Tsumer3*, Lina Bisharat3*, Jacob Rowe, MD3* and Donald Kufe, MD2*

1Beth Israel Deaconess Med. Ctr., Boston, MA
2Dana Farber Cancer Institute, Boston, MA
3Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa 31096, Israel

7:30 AM
Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) CellsClinically Relevant Abstract

Sarah Cooley1, Purvi Gada1*, David McKenna2*, Valarie McCullar1*, Susan Fautsch1*, Michael Verneris3*, Bruce R Blazar4*, Linda J Burns1*, Philip B McGlave, MD1, Daniel J. Weisdorf5* and Jeffrey S Miller5

1Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
2Clinical Cell Therapy Lab., Molecular & Cellular Therapeutics, Univ. of Minnesota, Saint Paul, MN
3Pediatrics, University of Minnesota, Minneapolis, MN
4Pediatrics, University of Minnesota, Minneaplis,, MN
5University of Minnesota, Minneapolis, MN

7:45 AM
Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCTClinically Relevant Abstract

Luca Vago1*, Serena Kimi Perna2*, Monica Zanussi3*, Benedetta Mazzi4*, Maria Teresa Lupo Stanghellini5*, Nicola Flavio Perrelli3*, Barbara Forno5*, Consuelo Corti5*, Massimo Bernardi5*, Jacopo Peccatori5*, Maurizio Ferrari3*, Silvano Rossini4*, Maria Grazia Roncarolo1*, Claudio Bordignon5, Chiara Bonini2, Fabio Ciceri5* and Katharina Fleischhauer4*

1H San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), IRCCS H San Raffaele, Milano, Italy
2Cancer Immunotherapy and Gene Therapy Program, IRCCS H San Raffaele, Milano, Italy
3Diagnostica e Ricerca S.p.A., IRCCS H San Raffaele, Milano, Italy
4Unit of Molecular Immunology of Transplantation, Immunohematology and Transfusion Medicine Service, IRCCS H San Raffaele, Milano, Italy
5Hematology and Bone Marrow Transplantation Unit, IRCCS H San Raffaele, Milano, Italy

8:00 AM
Management of Early Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation by Donor’s Dendritic Cell-Primed Cytokine-Induced Killer CellsClinically Relevant Abstract

Jing-Bo Wang*, Tong Wu, Jun-Fang Yang*, Jian-Ping Zhang*, Xing-Yu Cao*, Yu-Ming Yin*, Yuan Sun*, Rong-Mu Luo*, Dao-Pei Lu* and Chun-Rong Tong*

Beijing Daopei Hospital, Beijing, China

8:15 AM
Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms' Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid LeukemiaClinically Relevant Abstract

Zwi N. Berneman1, Ann Van de Velde1*, Ann Van Driessche1*, Nathalie Cools1*, Barbara Stein1*, Griet Nijs1*, Katrien Vermeulen1*, Katrien Pieters1*, Wilfried A. Schroyens1*, Alain P. Gadisseur1*, Inge Vrelust1*, I. Jolanda de Vries2*, David A. Price3*, Yusuke Oji4*, Haruo Sugiyama4* and Viggo F. Van Tendeloo1*

1University of Antwerp and Antwerp University Hospital (UZA), B-2650 Edegem, Belgium
2Radboud Universiteit Nijmegen, Nijmegen, Netherlands
3Cardiff University Medical School, Cardiff, United Kingdom
4Osaka University Graduate School of Medicine 1-7, Osaka, Japan

8:30 AM
Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without ChimerismClinically Relevant Abstract

Gerald A. Colvin, DO1, David Berz2*, Muthalagu Ramanathan, MD3*, Eric Winer, MD2, Loren D. Fast, PhD4, Gerald Jay Elfenbein, MD5 and Peter J. Quesenberry, MD6

1Rhode Island Hospital, Providence, RI
2Department of Medicine, Division Hematology/Oncology, Rhode Island Hospital, Providence, RI
3National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
4Division of Hem./Onc., Rhode Island Hosp./Brown Univ., Providence, RI
5Boston University, Franklin, MA
6Rhode Island Hospital, Center for Stem Cell Biology Research, Providence, RI

*signifies non-member of ASH